In addition,section 5 also states that: “Belter is responsible for delivering the minimum amount of sales regardless of circumstances.” (Id. Ex. G at 3 § 5.) Thus, at this stage in the proceedings, Belter has failed to demonstrate that the May 2, 2017 agreement unambiguously requiresCFDA approval as a condition precedent for all of the minimum sales requirements set----